JPMorgan Chase & Co. Trims BioNTech (NASDAQ:BNTX) Target Price to $91.00

BioNTech (NASDAQ:BNTX) had its price objective reduced by JPMorgan Chase & Co. from $94.00 to $91.00 in a research report report published on Thursday, Benzinga reports. They currently have an underweight rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. BMO Capital Markets cut their price objective on shares of BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a research report on Tuesday, May 7th. Hsbc Global Res raised shares of BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. HSBC raised shares of BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Evercore ISI assumed coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an inline rating and a $100.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a hold rating to a buy rating and set a $95.00 price objective for the company in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, BioNTech has an average rating of Moderate Buy and a consensus price target of $109.09.

BioNTech Trading Down 2.4 %

NASDAQ:BNTX opened at $85.19 on Thursday. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $125.83. The company has a market cap of $20.25 billion, a PE ratio of 170.38 and a beta of 0.23. The company has a 50 day simple moving average of $84.68 and a two-hundred day simple moving average of $89.73.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the firm posted ($0.86) EPS. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. Research analysts forecast that BioNTech will post -2.04 earnings per share for the current year.

Institutional Trading of BioNTech

Hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its stake in BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares in the last quarter. GAMMA Investing LLC lifted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in BioNTech in the 4th quarter worth $30,000. First Horizon Advisors Inc. purchased a new stake in BioNTech in the 4th quarter worth $38,000. Finally, Covestor Ltd lifted its stake in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.